 Rachel Rabinovitch
Concepts (352)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 62 | 2025 | 2393 | 3.780 |
Why?
| | Mastectomy, Segmental | 29 | 2025 | 107 | 2.060 |
Why?
| | Hodgkin Disease | 9 | 2026 | 172 | 1.630 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 9 | 2025 | 195 | 1.380 |
Why?
| | Brachytherapy | 10 | 2019 | 132 | 1.260 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 8 | 2025 | 61 | 1.260 |
Why?
| | Neoplasm Staging | 34 | 2020 | 1475 | 1.040 |
Why?
| | Neoplasm Recurrence, Local | 14 | 2025 | 1150 | 1.020 |
Why?
| | Mediastinal Neoplasms | 3 | 2017 | 53 | 1.020 |
Why?
| | Mastectomy | 8 | 2025 | 185 | 1.000 |
Why?
| | Radiotherapy, Adjuvant | 18 | 2025 | 222 | 0.980 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 14 | 2026 | 1969 | 0.890 |
Why?
| | Radiotherapy, Conformal | 7 | 2016 | 74 | 0.890 |
Why?
| | Lymphoma, B-Cell | 3 | 2026 | 141 | 0.850 |
Why?
| | Radiation Pneumonitis | 1 | 2024 | 31 | 0.820 |
Why?
| | Combined Modality Therapy | 25 | 2024 | 1271 | 0.820 |
Why?
| | Lymphoma, Follicular | 4 | 2023 | 56 | 0.750 |
Why?
| | Radiation Oncologists | 1 | 2021 | 3 | 0.690 |
Why?
| | Medical Oncology | 5 | 2026 | 340 | 0.660 |
Why?
| | Carcinoma, Ductal, Breast | 10 | 2016 | 90 | 0.560 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 6 | 2020 | 149 | 0.530 |
Why?
| | Lymphoma, Mantle-Cell | 3 | 2026 | 36 | 0.490 |
Why?
| | Female | 80 | 2025 | 79045 | 0.480 |
Why?
| | Breast | 3 | 2013 | 156 | 0.480 |
Why?
| | Mammography | 5 | 2019 | 166 | 0.470 |
Why?
| | Humans | 111 | 2026 | 145783 | 0.470 |
Why?
| | Middle Aged | 54 | 2026 | 36309 | 0.470 |
Why?
| | Cord Blood Stem Cell Transplantation | 3 | 2024 | 103 | 0.460 |
Why?
| | SEER Program | 7 | 2019 | 230 | 0.460 |
Why?
| | Aged, 80 and over | 20 | 2025 | 8347 | 0.440 |
Why?
| | Prognosis | 16 | 2024 | 4330 | 0.430 |
Why?
| | Radiotherapy Dosage | 13 | 2025 | 288 | 0.420 |
Why?
| | Transplantation Conditioning | 5 | 2024 | 191 | 0.410 |
Why?
| | Lymph Nodes | 5 | 2016 | 509 | 0.400 |
Why?
| | Aged | 40 | 2025 | 26217 | 0.400 |
Why?
| | Breast Neoplasms, Male | 1 | 2013 | 29 | 0.400 |
Why?
| | Kaplan-Meier Estimate | 6 | 2020 | 971 | 0.400 |
Why?
| | Proportional Hazards Models | 6 | 2022 | 1330 | 0.390 |
Why?
| | Neoplasms, Second Primary | 3 | 2020 | 102 | 0.390 |
Why?
| | Treatment Outcome | 21 | 2025 | 11794 | 0.380 |
Why?
| | BRCA2 Protein | 3 | 2020 | 68 | 0.380 |
Why?
| | Adult | 46 | 2026 | 40881 | 0.370 |
Why?
| | Radiosurgery | 2 | 2019 | 399 | 0.360 |
Why?
| | Radiotherapy | 6 | 2015 | 206 | 0.360 |
Why?
| | Prostatic Neoplasms | 4 | 2022 | 981 | 0.350 |
Why?
| | Lymphoma, Non-Hodgkin | 3 | 2021 | 124 | 0.350 |
Why?
| | Follow-Up Studies | 11 | 2024 | 5428 | 0.350 |
Why?
| | Healthcare Disparities | 1 | 2018 | 736 | 0.350 |
Why?
| | Delivery of Health Care | 1 | 2018 | 948 | 0.340 |
Why?
| | Survival Analysis | 9 | 2018 | 1378 | 0.340 |
Why?
| | Mammaplasty | 1 | 2013 | 142 | 0.330 |
Why?
| | BRCA1 Protein | 2 | 2020 | 82 | 0.300 |
Why?
| | Lymphoma | 2 | 2025 | 241 | 0.300 |
Why?
| | Whole-Body Irradiation | 5 | 2020 | 74 | 0.300 |
Why?
| | Disease-Free Survival | 8 | 2025 | 770 | 0.300 |
Why?
| | Hematopoietic Stem Cell Transplantation | 4 | 2024 | 699 | 0.300 |
Why?
| | Anthracyclines | 1 | 2009 | 49 | 0.290 |
Why?
| | Radiation Oncology | 5 | 2025 | 82 | 0.290 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2008 | 117 | 0.280 |
Why?
| | Neoplasms, Radiation-Induced | 3 | 2020 | 100 | 0.280 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2009 | 140 | 0.270 |
Why?
| | Bile Duct Diseases | 1 | 2008 | 13 | 0.270 |
Why?
| | Cholestasis, Intrahepatic | 1 | 2008 | 29 | 0.270 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2017 | 76 | 0.260 |
Why?
| | Neoplasm Grading | 6 | 2022 | 311 | 0.260 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2008 | 63 | 0.260 |
Why?
| | Graft vs Host Disease | 5 | 2024 | 279 | 0.260 |
Why?
| | Radiotherapy, Intensity-Modulated | 3 | 2014 | 142 | 0.260 |
Why?
| | Thoracic Vertebrae | 1 | 2007 | 83 | 0.250 |
Why?
| | United States | 16 | 2019 | 16126 | 0.240 |
Why?
| | Prostheses and Implants | 1 | 2007 | 137 | 0.240 |
Why?
| | Nutritional Support | 1 | 2006 | 39 | 0.230 |
Why?
| | Trastuzumab | 3 | 2024 | 118 | 0.230 |
Why?
| | Heart Diseases | 1 | 2009 | 341 | 0.230 |
Why?
| | Young Adult | 10 | 2026 | 14254 | 0.230 |
Why?
| | Orbital Neoplasms | 1 | 2025 | 28 | 0.220 |
Why?
| | Receptors, Estrogen | 4 | 2016 | 404 | 0.210 |
Why?
| | Survival Rate | 8 | 2019 | 2094 | 0.210 |
Why?
| | Transplantation, Haploidentical | 1 | 2024 | 23 | 0.210 |
Why?
| | Male | 28 | 2025 | 73011 | 0.200 |
Why?
| | Adolescent | 12 | 2026 | 22577 | 0.180 |
Why?
| | Time Factors | 5 | 2018 | 7134 | 0.180 |
Why?
| | Head and Neck Neoplasms | 2 | 2010 | 561 | 0.180 |
Why?
| | Flutamide | 2 | 2018 | 7 | 0.170 |
Why?
| | Goserelin | 2 | 2018 | 8 | 0.170 |
Why?
| | Analysis of Variance | 2 | 2015 | 1300 | 0.170 |
Why?
| | Neoplasm Invasiveness | 4 | 2019 | 508 | 0.170 |
Why?
| | Neoadjuvant Therapy | 3 | 2025 | 467 | 0.170 |
Why?
| | Patient Care Planning | 2 | 2021 | 170 | 0.170 |
Why?
| | Bone Neoplasms | 2 | 2018 | 265 | 0.160 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2006 | 641 | 0.160 |
Why?
| | Cause of Death | 2 | 2016 | 472 | 0.160 |
Why?
| | Survivorship | 1 | 2021 | 57 | 0.160 |
Why?
| | Androgen Antagonists | 2 | 2022 | 91 | 0.160 |
Why?
| | Deoxycytidine | 1 | 2022 | 220 | 0.160 |
Why?
| | Tumor Burden | 4 | 2016 | 325 | 0.160 |
Why?
| | Adenocarcinoma | 2 | 2018 | 926 | 0.160 |
Why?
| | Azacitidine | 1 | 2021 | 157 | 0.160 |
Why?
| | Immunoconjugates | 1 | 2021 | 138 | 0.150 |
Why?
| | Surgical Instruments | 1 | 2000 | 51 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2019 | 198 | 0.150 |
Why?
| | Clinical Trials as Topic | 5 | 2017 | 1062 | 0.150 |
Why?
| | Retrospective Studies | 12 | 2025 | 17330 | 0.150 |
Why?
| | Antineoplastic Agents | 7 | 2017 | 2219 | 0.150 |
Why?
| | Radiation Injuries | 3 | 2016 | 149 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2017 | 992 | 0.150 |
Why?
| | Biomarkers, Tumor | 2 | 2024 | 1329 | 0.150 |
Why?
| | Vidarabine | 3 | 2018 | 32 | 0.140 |
Why?
| | Patient Satisfaction | 2 | 2013 | 712 | 0.140 |
Why?
| | Leuprolide | 1 | 2018 | 21 | 0.140 |
Why?
| | Public Health Surveillance | 1 | 2018 | 83 | 0.140 |
Why?
| | Neoplasms | 2 | 2011 | 2913 | 0.140 |
Why?
| | Thiotepa | 1 | 2018 | 21 | 0.140 |
Why?
| | Aquaporin 4 | 1 | 2019 | 101 | 0.140 |
Why?
| | Necrosis | 1 | 2019 | 244 | 0.130 |
Why?
| | Diphosphonates | 1 | 2018 | 68 | 0.130 |
Why?
| | Rituximab | 2 | 2016 | 210 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 8 | 2022 | 1752 | 0.130 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2021 | 688 | 0.130 |
Why?
| | Imidazoles | 1 | 2018 | 247 | 0.130 |
Why?
| | Patient Care Management | 1 | 2017 | 56 | 0.130 |
Why?
| | Disease Management | 2 | 2018 | 653 | 0.120 |
Why?
| | Chemoradiotherapy | 1 | 2018 | 239 | 0.120 |
Why?
| | Lymphoma, Extranodal NK-T-Cell | 1 | 2016 | 11 | 0.120 |
Why?
| | Aromatase Inhibitors | 1 | 2017 | 81 | 0.120 |
Why?
| | Unilateral Breast Neoplasms | 1 | 2016 | 4 | 0.120 |
Why?
| | Practice Guidelines as Topic | 4 | 2017 | 1582 | 0.120 |
Why?
| | Multivariate Analysis | 3 | 2009 | 1547 | 0.120 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2016 | 20 | 0.120 |
Why?
| | Margins of Excision | 1 | 2016 | 50 | 0.120 |
Why?
| | Recurrence | 5 | 2018 | 1139 | 0.120 |
Why?
| | Datasets as Topic | 1 | 2016 | 118 | 0.110 |
Why?
| | Esthetics | 2 | 2013 | 50 | 0.110 |
Why?
| | Chemotherapy, Adjuvant | 6 | 2017 | 427 | 0.110 |
Why?
| | Biopsy | 5 | 2022 | 1082 | 0.110 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 266 | 0.110 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 217 | 0.110 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2012 | 73 | 0.110 |
Why?
| | Prostate-Specific Antigen | 3 | 2022 | 161 | 0.110 |
Why?
| | Risk Factors | 5 | 2022 | 10919 | 0.110 |
Why?
| | Carcinoma | 1 | 2016 | 227 | 0.100 |
Why?
| | Gene Expression Profiling | 3 | 2017 | 1777 | 0.100 |
Why?
| | Quality of Life | 2 | 2025 | 3211 | 0.100 |
Why?
| | Patient Selection | 4 | 2016 | 739 | 0.100 |
Why?
| | Receptors, Progesterone | 2 | 2013 | 244 | 0.100 |
Why?
| | Insurance Coverage | 1 | 2016 | 244 | 0.100 |
Why?
| | Cancer Survivors | 1 | 2019 | 338 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2020 | 2399 | 0.100 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 95 | 0.100 |
Why?
| | Societies, Medical | 4 | 2016 | 900 | 0.100 |
Why?
| | Propensity Score | 1 | 2016 | 377 | 0.100 |
Why?
| | Beauty | 1 | 2013 | 19 | 0.100 |
Why?
| | Immunotherapy, Adoptive | 3 | 2023 | 343 | 0.100 |
Why?
| | Practice Patterns, Physicians' | 3 | 2017 | 1372 | 0.100 |
Why?
| | Lymphatic Irradiation | 2 | 2010 | 11 | 0.100 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2016 | 218 | 0.100 |
Why?
| | Diagnostic Self Evaluation | 1 | 2013 | 24 | 0.100 |
Why?
| | Axilla | 3 | 2007 | 51 | 0.100 |
Why?
| | Confidence Intervals | 1 | 2013 | 330 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1450 | 0.090 |
Why?
| | Age Distribution | 1 | 2013 | 404 | 0.090 |
Why?
| | Lymphatic Metastasis | 4 | 2019 | 336 | 0.090 |
Why?
| | Sex Distribution | 1 | 2013 | 388 | 0.090 |
Why?
| | Prospective Studies | 8 | 2022 | 8078 | 0.090 |
Why?
| | Palliative Care | 2 | 2018 | 1022 | 0.090 |
Why?
| | Carcinoma, Renal Cell | 1 | 1994 | 230 | 0.080 |
Why?
| | Immunotherapy | 1 | 2016 | 668 | 0.080 |
Why?
| | Cyclophosphamide | 2 | 2009 | 272 | 0.080 |
Why?
| | Health Physics | 1 | 2010 | 7 | 0.080 |
Why?
| | Guideline Adherence | 2 | 2017 | 587 | 0.080 |
Why?
| | Immunosuppressive Agents | 3 | 2006 | 838 | 0.080 |
Why?
| | Four-Dimensional Computed Tomography | 1 | 2010 | 38 | 0.080 |
Why?
| | Lung Neoplasms | 2 | 2018 | 2668 | 0.080 |
Why?
| | Boronic Acids | 1 | 2010 | 36 | 0.080 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1505 | 0.080 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2010 | 116 | 0.070 |
Why?
| | Kidney Neoplasms | 1 | 1994 | 415 | 0.070 |
Why?
| | Doxorubicin | 2 | 2009 | 403 | 0.070 |
Why?
| | Pyrazines | 1 | 2010 | 94 | 0.070 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2009 | 63 | 0.070 |
Why?
| | Thrombophilia | 1 | 2009 | 89 | 0.070 |
Why?
| | Mutation | 1 | 2020 | 4090 | 0.070 |
Why?
| | Databases as Topic | 1 | 2008 | 71 | 0.070 |
Why?
| | Iridium Radioisotopes | 1 | 2007 | 4 | 0.070 |
Why?
| | Movement | 1 | 2010 | 293 | 0.070 |
Why?
| | Diagnostic Imaging | 1 | 2010 | 337 | 0.070 |
Why?
| | Positron-Emission Tomography | 3 | 2017 | 343 | 0.070 |
Why?
| | Sex Factors | 1 | 2013 | 2110 | 0.060 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2008 | 196 | 0.060 |
Why?
| | Prednisone | 1 | 2008 | 226 | 0.060 |
Why?
| | Comorbidity | 3 | 2017 | 1662 | 0.060 |
Why?
| | Registries | 1 | 2016 | 2410 | 0.060 |
Why?
| | Syndrome | 1 | 2008 | 381 | 0.060 |
Why?
| | Fatigue | 2 | 2025 | 366 | 0.060 |
Why?
| | Incidence | 1 | 2013 | 2934 | 0.060 |
Why?
| | Sternum | 1 | 2006 | 27 | 0.060 |
Why?
| | Stomatitis | 1 | 2006 | 15 | 0.060 |
Why?
| | Age Factors | 2 | 2017 | 3346 | 0.060 |
Why?
| | Radiology | 1 | 2008 | 174 | 0.060 |
Why?
| | Carcinoma, Small Cell | 1 | 2006 | 172 | 0.060 |
Why?
| | Conjunctival Neoplasms | 1 | 2025 | 7 | 0.060 |
Why?
| | Risk Assessment | 2 | 2025 | 3752 | 0.060 |
Why?
| | Mycophenolic Acid | 1 | 2006 | 119 | 0.060 |
Why?
| | Carcinoma, Ductal | 1 | 2005 | 10 | 0.060 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 1 | 2025 | 19 | 0.050 |
Why?
| | Nomograms | 1 | 2025 | 59 | 0.050 |
Why?
| | Child | 3 | 2024 | 22740 | 0.050 |
Why?
| | Tacrolimus | 1 | 2006 | 196 | 0.050 |
Why?
| | Stem Cell Transplantation | 1 | 2006 | 189 | 0.050 |
Why?
| | Mastectomy, Modified Radical | 2 | 2000 | 6 | 0.050 |
Why?
| | Living Donors | 1 | 2006 | 282 | 0.050 |
Why?
| | Anemia, Sideroblastic | 1 | 2003 | 4 | 0.050 |
Why?
| | Radiography | 2 | 2010 | 853 | 0.050 |
Why?
| | Reproducibility of Results | 5 | 2012 | 3418 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 3 | 2009 | 2770 | 0.050 |
Why?
| | Drug Administration Schedule | 2 | 2018 | 782 | 0.050 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2019 | 883 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 3 | 2019 | 3916 | 0.040 |
Why?
| | Mass Screening | 1 | 2010 | 1361 | 0.040 |
Why?
| | Lymph Node Excision | 3 | 2009 | 173 | 0.040 |
Why?
| | Professional Staff Committees | 1 | 2001 | 10 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2007 | 869 | 0.040 |
Why?
| | Antigens, CD19 | 1 | 2021 | 128 | 0.040 |
Why?
| | Organ Size | 2 | 2013 | 461 | 0.040 |
Why?
| | Allografts | 1 | 2021 | 152 | 0.040 |
Why?
| | Weight Loss | 1 | 2006 | 859 | 0.040 |
Why?
| | Automation | 1 | 2020 | 104 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2026 | 981 | 0.040 |
Why?
| | Carcinoma, Lobular | 1 | 2000 | 56 | 0.040 |
Why?
| | Risk Management | 1 | 2020 | 82 | 0.040 |
Why?
| | Quality Assurance, Health Care | 2 | 2012 | 342 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2020 | 177 | 0.040 |
Why?
| | Respiration | 2 | 2010 | 207 | 0.040 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2021 | 280 | 0.040 |
Why?
| | Salvage Therapy | 1 | 2000 | 165 | 0.040 |
Why?
| | Kallikreins | 1 | 2018 | 26 | 0.040 |
Why?
| | Workflow | 1 | 2020 | 183 | 0.040 |
Why?
| | Myeloablative Agonists | 1 | 2018 | 23 | 0.030 |
Why?
| | Fetal Blood | 1 | 2020 | 327 | 0.030 |
Why?
| | Maximum Tolerated Dose | 2 | 2010 | 211 | 0.030 |
Why?
| | Osteoblasts | 1 | 2018 | 145 | 0.030 |
Why?
| | Sulfonamides | 1 | 2021 | 583 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2018 | 205 | 0.030 |
Why?
| | Genomics | 1 | 2022 | 830 | 0.030 |
Why?
| | Aftercare | 1 | 2019 | 222 | 0.030 |
Why?
| | Neutropenia | 2 | 2010 | 154 | 0.030 |
Why?
| | Canada | 1 | 2018 | 432 | 0.030 |
Why?
| | Retreatment | 1 | 2017 | 80 | 0.030 |
Why?
| | Asparaginase | 1 | 2016 | 32 | 0.030 |
Why?
| | Fat Necrosis | 1 | 2016 | 12 | 0.030 |
Why?
| | Socioeconomic Factors | 2 | 2017 | 1327 | 0.030 |
Why?
| | Metaplasia | 1 | 2016 | 57 | 0.030 |
Why?
| | Safety | 1 | 2018 | 358 | 0.030 |
Why?
| | Ultrasonography | 1 | 2000 | 788 | 0.030 |
Why?
| | North America | 1 | 2016 | 304 | 0.030 |
Why?
| | Herpesvirus 4, Human | 1 | 2016 | 172 | 0.030 |
Why?
| | Survivors | 1 | 2019 | 523 | 0.030 |
Why?
| | Heart | 2 | 2010 | 626 | 0.030 |
Why?
| | Europe | 1 | 2016 | 421 | 0.030 |
Why?
| | Genetic Variation | 1 | 2020 | 977 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1998 | 0.030 |
Why?
| | Gene Rearrangement | 1 | 2016 | 156 | 0.030 |
Why?
| | Postmenopause | 2 | 2009 | 394 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2016 | 322 | 0.030 |
Why?
| | DNA, Viral | 1 | 2016 | 356 | 0.030 |
Why?
| | Advisory Committees | 1 | 2016 | 229 | 0.030 |
Why?
| | Catheterization, Peripheral | 1 | 2016 | 120 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 241 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2016 | 169 | 0.030 |
Why?
| | Radioimmunotherapy | 1 | 2014 | 25 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1083 | 0.030 |
Why?
| | Actuarial Analysis | 1 | 1994 | 16 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 441 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 364 | 0.020 |
Why?
| | Treatment Failure | 1 | 1994 | 360 | 0.020 |
Why?
| | Child, Preschool | 1 | 2008 | 11868 | 0.020 |
Why?
| | Mass Media | 1 | 2012 | 39 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2025 | 6085 | 0.020 |
Why?
| | Palpation | 1 | 2010 | 15 | 0.020 |
Why?
| | Ultrasonography, Mammary | 1 | 2010 | 17 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2001 | 1925 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2139 | 0.020 |
Why?
| | Urologic Neoplasms | 1 | 2010 | 31 | 0.020 |
Why?
| | Thoracic Neoplasms | 1 | 2010 | 39 | 0.020 |
Why?
| | Bortezomib | 1 | 2010 | 54 | 0.020 |
Why?
| | Lymphopenia | 1 | 2010 | 62 | 0.020 |
Why?
| | Subcutaneous Fat | 1 | 2010 | 79 | 0.020 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1331 | 0.020 |
Why?
| | Nausea | 1 | 2010 | 112 | 0.020 |
Why?
| | Soft Tissue Neoplasms | 1 | 2010 | 131 | 0.020 |
Why?
| | Pregnancy Trimester, Second | 1 | 2009 | 85 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 428 | 0.020 |
Why?
| | Genital Neoplasms, Female | 1 | 2010 | 99 | 0.020 |
Why?
| | Radiation Dosage | 1 | 2010 | 193 | 0.020 |
Why?
| | Pregnancy Trimester, First | 1 | 2009 | 139 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2875 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 428 | 0.020 |
Why?
| | Calcinosis | 1 | 2010 | 234 | 0.020 |
Why?
| | Diarrhea | 1 | 2010 | 193 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 187 | 0.020 |
Why?
| | Premenopause | 1 | 2009 | 125 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 2968 | 0.020 |
Why?
| | Observer Variation | 1 | 2009 | 357 | 0.020 |
Why?
| | Perimenopause | 1 | 2008 | 69 | 0.020 |
Why?
| | Credentialing | 1 | 2007 | 21 | 0.020 |
Why?
| | Quality Control | 1 | 2008 | 161 | 0.020 |
Why?
| | Fibrosis | 1 | 2010 | 561 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2008 | 328 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1851 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 740 | 0.020 |
Why?
| | Benchmarking | 1 | 2007 | 191 | 0.010 |
Why?
| | Medicare | 1 | 2012 | 904 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2010 | 1512 | 0.010 |
Why?
| | Lung | 2 | 2010 | 4116 | 0.010 |
Why?
| | Taxoids | 1 | 2006 | 114 | 0.010 |
Why?
| | Etoposide | 1 | 2006 | 168 | 0.010 |
Why?
| | Carboplatin | 1 | 2006 | 164 | 0.010 |
Why?
| | Signal Transduction | 1 | 2019 | 5224 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 2028 | 0.010 |
Why?
| | Genital Diseases, Male | 1 | 1985 | 16 | 0.010 |
Why?
| | Colorado | 2 | 2010 | 4556 | 0.010 |
Why?
| | Genital Diseases, Female | 1 | 1985 | 31 | 0.010 |
Why?
| | Biomarkers | 1 | 2016 | 4302 | 0.010 |
Why?
| | Chlamydia trachomatis | 1 | 1985 | 49 | 0.010 |
Why?
| | Siblings | 1 | 2006 | 196 | 0.010 |
Why?
| | Pharynx | 1 | 1985 | 59 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2008 | 1723 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2007 | 442 | 0.010 |
Why?
| | Cisplatin | 1 | 2006 | 345 | 0.010 |
Why?
| | Rectum | 1 | 1985 | 182 | 0.010 |
Why?
| | Hematologic Neoplasms | 1 | 2006 | 168 | 0.010 |
Why?
| | Antilymphocyte Serum | 1 | 2003 | 57 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2007 | 1115 | 0.010 |
Why?
| | Sexually Transmitted Diseases | 1 | 1985 | 168 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2003 | 305 | 0.010 |
Why?
| | Graft Rejection | 1 | 2006 | 521 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 2003 | 419 | 0.010 |
Why?
| | Skin Neoplasms | 1 | 2009 | 853 | 0.010 |
Why?
| | Transplantation, Heterologous | 1 | 2001 | 170 | 0.010 |
Why?
| | Organizational Objectives | 1 | 2001 | 67 | 0.010 |
Why?
| | Hospitals, Private | 1 | 1999 | 12 | 0.010 |
Why?
| | Hospitals, County | 1 | 1999 | 11 | 0.010 |
Why?
| | Hospitals, University | 1 | 1999 | 176 | 0.010 |
Why?
| | Forecasting | 1 | 2001 | 390 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2009 | 6465 | 0.010 |
Why?
| | Reoperation | 1 | 2000 | 637 | 0.010 |
Why?
| | Pregnancy | 1 | 2009 | 7216 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 1999 | 777 | 0.010 |
Why?
| | Bacteriological Techniques | 1 | 1985 | 66 | 0.000 |
Why?
| | Chlamydia Infections | 1 | 1985 | 79 | 0.000 |
Why?
| | Risk | 1 | 1985 | 923 | 0.000 |
Why?
| | Sexual Behavior | 1 | 1985 | 495 | 0.000 |
Why?
|
|
Rabinovitch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|